Rheumatoid Arthritis Management Strategies: New Insights for Managed Care Web Activity

Release Date: January 28, 2019
Expiration Date: July 31, 2020
Estimated Time to Complete Activity: 1.25 hours
Compatible with all modern browsers and mobile devices

EXPERT FACULTY


	James Kenney, Jr., RPh, MBA Manager, Specialty and Pharmacy Contracts Harvard Pilgrim Health Care Click here for biography

	Robin Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA Click here for biography

TARGET AUDIENCE

Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

STATEMENT OF NEED/PROGRAM OVERVIEW

Rheumatoid arthritis (RA) is an autoimmune disease affecting nearly 1.5 million adult Americans. RA involves inflammation of the synovium with progressive erosion of bone leading in most cases to loss of joint function and disability. There are 2.5 times as many women as men with RA and the onset usually occurs in middle-age; however, RA can occur in young adults as well. A cure for RA remains elusive, but effective drugs are available to manage symptoms and minimize disease progression. In addition to medications, regular performance of self-management techniques, including physical activity, are known to reduce pain and disability. RA treatment goals include controlling pain and inflammation, achieving the lowest disease activity, and ultimately, remission.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate improved ability to:

Review recent insights into the pathophysiology of RA and emerging treatment strategies
Discuss the safety, efficacy, and attributes of emerging therapies
Align managed care RA treatment algorithms with recent clinical trial data
Employ specialty pharmacy and disease management services for RA patients
Describe care pathways and their application as a cost management tool in RA

ACCREDITATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-19-578-H01-P)

Type of Activity: Application

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
James Kenney, Jr., RPh, MBA	Mr. Kenney has nothing to disclose
Robin Dore, MD	Consulting fees from Amgen, AbbVie, Novartis, Lilly; Non-CME/CE Services fees received directly from Amgen, AbbVie, Lilly, Pfizer, Novartis, UCB; Contracted Research fees from Amgen, AbbVie, Gilead, Novartis, Lilly

The PIM planners and managers have nothing to disclose.
The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of January 28, 2019 through July 31, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.